Arima's top competitors are CosmosID, Phase Genomics and 10X Genomics.
Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. “Arima has the potential to unlock novel genomic applications by leading the community’s transition from focusing on sequence alone toward sequence and structure.”SAN DIEGO — Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. Watch every session from the AI event of the year“Since the initial product launch in 2018, Arima has shown remarkable success in achieving customer confidence as demonstrated by rapid customer and revenue growth,” said Siddarth Selvaraj, CEO and Co-founder of Arima Genomics, Inc. “We are excited to invite our investors to Arima’s fascinating journey and thrilled to partner with them to drive the next phase of growth.”SAN DIEGO–(BUSINESS WIRE)–February 24, 2020–Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. Please try again365 Bloor Street East, Toronto, Ontario, M4W 3L4“Agilent invests in industry partners to advance the development of new technologies that will accelerate the pace of scientific discoveries,” said Tad Weems, Managing Director of Agilent’s Early Stage Partnership Program. © 2020 Financial Post, a division of Postmedia Network Inc. All rights reserved. “Arima has the potential to unlock novel genomic applications by leading the community’s transition from focusing on sequence alone toward sequence and structure.” See Arima's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund. SAN DIEGO–(BUSINESS WIRE)–Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. Unauthorized distribution, transmission or republication strictly prohibited.“Since the initial product launch in 2018, Arima has shown remarkable success in achieving customer confidence as demonstrated by rapid customer and revenue growth,” said Siddarth Selvaraj, CEO and Co-founder of Arima Genomics, Inc. “We are excited to invite our investors to Arima’s fascinating journey and thrilled to partner with them to drive the next phase of growth.”Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.The next issue of Top Stories Newsletter will soon be in your inbox.A welcome email is on its way. Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund.“Agilent invests in industry partners to advance the development of new technologies that will accelerate the pace of scientific discoveries,” said Tad Weems, Managing Director of Agilent’s Early Stage Partnership Program.
If you don't see it please check your junk folder.We encountered an issue signing you up.
Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund.There was an error, please provide a valid email address. SAN DIEGO — Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their …
To learn more, please visit www.arimagenomics.com . Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund. Arima Genomics, Inc. is a biotechnology company that aims to accelerate the understanding of genome sequence and structure. SAN DIEGO--(BUSINESS WIRE)-- Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing.Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund. The funding will also support scaling of Arima’s operations and enhancing customer service and support experience.